This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ironwood (IRWD) Q3 Earnings Top, Sales Hurt by Lower Price
by Zacks Equity Research
Ironwood (IRWD) witnesses flat year-over-year sales as growth in demand for Linzess gets partially offset by lower net price of the drug. The company maintains revenue guidance. Stock down.
Ironwood Pharmaceuticals (IRWD) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 6.45% and -1.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch's (BHC) NOV03 for Dry Eye Disease Meets Study Goal
by Zacks Equity Research
Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.
Ziopharm (ZIOP) Down on Workforce Reduction Announcement
by Zacks Equity Research
Ziopharm's (ZIOP) stock price falls after the announcement of several restructuring changes to advance the TCR program.
6 High Earnings Yield Picks That You Shouldn't Miss Out On
by Rimmi Singhi
Reap handsome rewards by investing in high earnings yield stocks including MT, MTH, SIMO, DFIN, IRWD, and COLL.
Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy
by Zacks Equity Research
Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.
Roche (RHHBY) Lung Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Roche (RHHBY) gets a positive CHMP opinion for Gavreto for the treatment of adult patients with RET fusion-positive advanced NSCLC.
Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) reports mixed data from the phase IIb study evaluating AR-15512 for treating dry eye disease. Resultantly, the stock declines in after-market trading on Sep 15.
Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy
by Zacks Equity Research
Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.
Horizon (HZNP) Begins Phase IV Study on Tepezza for Chronic TED
by Zacks Equity Research
Horizon (HZNP) enrolls the first patient in a phase IV study evaluating the safety and efficacy of Tepezza for the treatment of chronic (inactive) thyroid eye disease.
RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis
by Zacks Equity Research
Opaganib, Redhill's (RDHL) candidate for COVID-19, achieves a significant reduction in kidney fibrosis in preclinical studies.
Bayer's (BAYRY) Chronic Cough Candidate Meets Efficacy Goal
by Zacks Equity Research
Bayer (BAYRY) posts positive data from the phase IIb PAGANINI study which is evaluating its investigational candidate, eliapixant, in patients with refractory chronic cough.
Takeda (TAK) Hematology Candidate Fails in Late-Stage Study
by Zacks Equity Research
Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone, a potential treatment for schizophrenia.
Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study
by Zacks Equity Research
The FDA clears Anixa Biosciences' (ANIX) application to initiate clinical studies for its ovarian cancer CAR-T therapy. The stock rises following the announcement.
Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study
by Zacks Equity Research
Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.
Fibrogen (FGEN)/Astellas Get EU Nod for Roxadustat for Anemia
by Zacks Equity Research
Roxadustat, FibroGen (FGEN) and Astellas' candidate for symptomatic anemia of chronic kidney disease, secures EU approval. The drug is to be sold in Europe under the brand name Evrenzo.
Jazz's (JAZZ) Xywav Gets FDA Nod for Idiopathic Hypersomnia
by Zacks Equity Research
Jazz's (JAZZ) Xywav gets FDA approval for new indication, idiopathic hypersomnia. Following approval, Xywav becomes the first drug for treatment of this sleep disorder.
FibroGen's (FGEN) Drug for Anemia of CKD Gets CRL From FDA
by Zacks Equity Research
NDA for roxadustat, FibroGen's (FGEN) candidate for anemia of chronic kidney disease, fails to secure approval as the FDA requests additional clinical data on the drug. The stock declines resultantly.
5 High Earnings Yield Picks to Reap Handsome Rewards
by Rimmi Singhi
Invest in top-ranked high earnings yield stocks like DFIN, IRWD, LEN, EAT, SGH to strengthen your portfolio.
Jazz's (JAZZ) Epidyolex Gets Approval for New Indication in UK
by Zacks Equity Research
Jazz's (JAZZ) unit GW Pharmaceuticals' Epidyolex (cannabidiol) gets a regulatory nod for a new indication in the United Kingdom. Following this announcement, stock prices fell.
Reata (RETA) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Reata (RETA) beats estimates for earnings and sales. Stock down on negative regulatory update on lead pipeline candidate, bardoxolone.
Sanofi (SNY) Pompe Disease Drug Receives FDA's Approval
by Zacks Equity Research
The FDA gives approval to Sanofi's (SNY) Nexviazyme (avalglucosidase alfa) for treating late-onset Pompe disease.
Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut
by Zacks Equity Research
Puma Biotech (PBYI) reports better-than-expected Q2 earnings and sales. It lowers 2021 Nerlynx sales guidance.